TY - JOUR
T1 - Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete Remission
AU - Kurosawa, Saiko
AU - Yamaguchi, Takuhiro
AU - Uchida, Naoyuki
AU - Miyawaki, Shuichi
AU - Usuki, Kensuke
AU - Watanabe, Masato
AU - Yamashita, Takuya
AU - Kanamori, Heiwa
AU - Tomiyama, Junji
AU - Nawa, Yuichiro
AU - Yano, Shingo
AU - Takeuchi, Jin
AU - Yakushiji, Kazuaki
AU - Sano, Fumiaki
AU - Uoshima, Nobuhiko
AU - Yano, Takahiro
AU - Nannya, Yasuhito
AU - Moriuchi, Yukiyoshi
AU - Miura, Ikuo
AU - Takaue, Yoichi
AU - Fukuda, Takahiro
N1 - Funding Information:
Financial disclosure: This work was supported by grants from the Japanese Ministry of Health, Labour and Welfare and the Advanced Clinical Research Organization . The results were presented at the 51st annual meeting of the American Society of Hematology, New Orleans, LA, on December 7, 2009.
PY - 2011/3
Y1 - 2011/3
N2 - The benefits of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myelogenous leukemia (AML) in first complete remission (CR1) have mostly been evaluated in younger patients. Although favorable outcomes of allo-HCT over chemotherapy have been reported with the use of reduced-intensity conditioning (RIC) regimens in elderly patients with AML in CR1, information is still limited, especially on the effects of cytogenetic risks and donor sources. We collected data from AML patients aged 50 to 70 years who achieved CR1, and compared the outcome in 152 patients who underwent allo-HCT in CR1 (HCT group) to that in 884 patients who were treated with chemotherapy (CTx group). The cumulative incidence of relapse in the HCT group was significantly lower than that in the CTx group (22% versus 62%). Both overall survival (OS) and relapse-free survival (RFS) were significantly improved in the HCT group (OS: 62% versus 51%, P = .012), not only in the whole population, but also in the intermediate-risk group. Among patients who had a suitable related donor, the outcomes in the HCT group were significantly better than those in the CTx group. The introduction of appropriate treatment strategies that include allo-HCT may improve the outcome in elderly patients with AML in CR1.
AB - The benefits of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myelogenous leukemia (AML) in first complete remission (CR1) have mostly been evaluated in younger patients. Although favorable outcomes of allo-HCT over chemotherapy have been reported with the use of reduced-intensity conditioning (RIC) regimens in elderly patients with AML in CR1, information is still limited, especially on the effects of cytogenetic risks and donor sources. We collected data from AML patients aged 50 to 70 years who achieved CR1, and compared the outcome in 152 patients who underwent allo-HCT in CR1 (HCT group) to that in 884 patients who were treated with chemotherapy (CTx group). The cumulative incidence of relapse in the HCT group was significantly lower than that in the CTx group (22% versus 62%). Both overall survival (OS) and relapse-free survival (RFS) were significantly improved in the HCT group (OS: 62% versus 51%, P = .012), not only in the whole population, but also in the intermediate-risk group. Among patients who had a suitable related donor, the outcomes in the HCT group were significantly better than those in the CTx group. The introduction of appropriate treatment strategies that include allo-HCT may improve the outcome in elderly patients with AML in CR1.
KW - Acute myelogenous leukemia
KW - Allogeneic hematopoietic cell transplantation
KW - Elderly patients
KW - First complete remission
UR - http://www.scopus.com/inward/record.url?scp=79551685595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551685595&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2010.07.013
DO - 10.1016/j.bbmt.2010.07.013
M3 - Article
C2 - 20667478
AN - SCOPUS:79551685595
SN - 1083-8791
VL - 17
SP - 401
EP - 411
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 3
ER -